SeaBioTech: from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology

RuAngelie Edrada-Ebel, Arnthor Ævarsson, Paraskevi Polymenakou, Ute Hentschel, Daniele Carettoni, John Day, David Green, Guðmundur Óli Hreggviðsson, Linda Harvey, Brian McNeil

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge exchange.

SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep-sea oligotrophic basins of the Eastern Mediterranean Sea and underexplored areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds. This chapter describes the 4 years of activity in the SeaBioTech project, which resulted in a robust, validated workflow suitable for evaluating unexplored activities in marine samples to prioritize potential products for a biotechnological pipeline. An improved integrated methodology involving metagenomics and metabolomics was extensively utilized to prioritize five extremophiles as potential antibiotics, anticancer drugs and novel drugs against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A centralized biobank repository, which included a database of information, was established for future bioprospecting activities. For future marine bioprospecting activities, a harmonized legal position was put together in collaboration with other EU-FP7 blue biotechnology projects.
LanguageEnglish
Title of host publicationGrand Challenges in Marine Biotechnology
EditorsPabulo H. Rampelotto, Antonio Trincone
Place of PublicationCham
PublisherSpringer
Chapter12
Pages451-504
Number of pages54
ISBN (Print)9783319690742, 9783319690759
DOIs
Publication statusPublished - 28 May 2018

Publication series

NameGrand Challenges in Biology and Biotechnology
PublisherSpringer
ISSN (Print)2367-1017

Fingerprint

Biodiversity
Biotechnology
Pipelines
Pharmaceutical Preparations
Hydrothermal Vents
Mediterranean Sea
Iceland
Metagenomics
Aquaculture
Functional Food
Metabolomics
Cosmetics
Workflow
Vents
Excipients
Metabolic Diseases
Jurisprudence
Genomics
Bioactivity
Biological Products

Keywords

  • SeaBioTech
  • marine endosymbiotic bacteria
  • biotechnological pipeline

Cite this

Edrada-Ebel, R., Ævarsson, A., Polymenakou, P., Hentschel, U., Carettoni, D., Day, J., ... McNeil, B. (2018). SeaBioTech: from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology. In P. H. Rampelotto, & A. Trincone (Eds.), Grand Challenges in Marine Biotechnology (pp. 451-504). (Grand Challenges in Biology and Biotechnology). Cham: Springer. https://doi.org/10.1007/978-3-319-69075-9_12
Edrada-Ebel, RuAngelie ; Ævarsson, Arnthor ; Polymenakou, Paraskevi ; Hentschel, Ute ; Carettoni, Daniele ; Day, John ; Green, David ; Hreggviðsson, Guðmundur Óli ; Harvey, Linda ; McNeil, Brian. / SeaBioTech : from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology. Grand Challenges in Marine Biotechnology. editor / Pabulo H. Rampelotto ; Antonio Trincone. Cham : Springer, 2018. pp. 451-504 (Grand Challenges in Biology and Biotechnology).
@inbook{b901a42d3f3b4291a632c452d30185aa,
title = "SeaBioTech: from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology",
abstract = "SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge exchange. SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep-sea oligotrophic basins of the Eastern Mediterranean Sea and underexplored areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds. This chapter describes the 4 years of activity in the SeaBioTech project, which resulted in a robust, validated workflow suitable for evaluating unexplored activities in marine samples to prioritize potential products for a biotechnological pipeline. An improved integrated methodology involving metagenomics and metabolomics was extensively utilized to prioritize five extremophiles as potential antibiotics, anticancer drugs and novel drugs against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A centralized biobank repository, which included a database of information, was established for future bioprospecting activities. For future marine bioprospecting activities, a harmonized legal position was put together in collaboration with other EU-FP7 blue biotechnology projects.",
keywords = "SeaBioTech, marine endosymbiotic bacteria, biotechnological pipeline",
author = "RuAngelie Edrada-Ebel and Arnthor {\AE}varsson and Paraskevi Polymenakou and Ute Hentschel and Daniele Carettoni and John Day and David Green and Hreggvi{\dh}sson, {Gu{\dh}mundur {\'O}li} and Linda Harvey and Brian McNeil",
year = "2018",
month = "5",
day = "28",
doi = "10.1007/978-3-319-69075-9_12",
language = "English",
isbn = "9783319690742",
series = "Grand Challenges in Biology and Biotechnology",
publisher = "Springer",
pages = "451--504",
editor = "Rampelotto, {Pabulo H. } and Antonio Trincone",
booktitle = "Grand Challenges in Marine Biotechnology",

}

Edrada-Ebel, R, Ævarsson, A, Polymenakou, P, Hentschel, U, Carettoni, D, Day, J, Green, D, Hreggviðsson, GÓ, Harvey, L & McNeil, B 2018, SeaBioTech: from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology. in PH Rampelotto & A Trincone (eds), Grand Challenges in Marine Biotechnology. Grand Challenges in Biology and Biotechnology, Springer, Cham, pp. 451-504. https://doi.org/10.1007/978-3-319-69075-9_12

SeaBioTech : from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology. / Edrada-Ebel, RuAngelie; Ævarsson, Arnthor ; Polymenakou, Paraskevi ; Hentschel, Ute ; Carettoni, Daniele ; Day, John; Green, David; Hreggviðsson, Guðmundur Óli ; Harvey, Linda; McNeil, Brian.

Grand Challenges in Marine Biotechnology. ed. / Pabulo H. Rampelotto; Antonio Trincone. Cham : Springer, 2018. p. 451-504 (Grand Challenges in Biology and Biotechnology).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - SeaBioTech

T2 - from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology

AU - Edrada-Ebel, RuAngelie

AU - Ævarsson, Arnthor

AU - Polymenakou, Paraskevi

AU - Hentschel, Ute

AU - Carettoni, Daniele

AU - Day, John

AU - Green, David

AU - Hreggviðsson, Guðmundur Óli

AU - Harvey, Linda

AU - McNeil, Brian

PY - 2018/5/28

Y1 - 2018/5/28

N2 - SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge exchange. SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep-sea oligotrophic basins of the Eastern Mediterranean Sea and underexplored areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds. This chapter describes the 4 years of activity in the SeaBioTech project, which resulted in a robust, validated workflow suitable for evaluating unexplored activities in marine samples to prioritize potential products for a biotechnological pipeline. An improved integrated methodology involving metagenomics and metabolomics was extensively utilized to prioritize five extremophiles as potential antibiotics, anticancer drugs and novel drugs against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A centralized biobank repository, which included a database of information, was established for future bioprospecting activities. For future marine bioprospecting activities, a harmonized legal position was put together in collaboration with other EU-FP7 blue biotechnology projects.

AB - SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge exchange. SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep-sea oligotrophic basins of the Eastern Mediterranean Sea and underexplored areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds. This chapter describes the 4 years of activity in the SeaBioTech project, which resulted in a robust, validated workflow suitable for evaluating unexplored activities in marine samples to prioritize potential products for a biotechnological pipeline. An improved integrated methodology involving metagenomics and metabolomics was extensively utilized to prioritize five extremophiles as potential antibiotics, anticancer drugs and novel drugs against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A centralized biobank repository, which included a database of information, was established for future bioprospecting activities. For future marine bioprospecting activities, a harmonized legal position was put together in collaboration with other EU-FP7 blue biotechnology projects.

KW - SeaBioTech

KW - marine endosymbiotic bacteria

KW - biotechnological pipeline

UR - https://link.springer.com/book/10.1007/978-3-319-69075-9

U2 - 10.1007/978-3-319-69075-9_12

DO - 10.1007/978-3-319-69075-9_12

M3 - Chapter

SN - 9783319690742

SN - 9783319690759

T3 - Grand Challenges in Biology and Biotechnology

SP - 451

EP - 504

BT - Grand Challenges in Marine Biotechnology

A2 - Rampelotto, Pabulo H.

A2 - Trincone, Antonio

PB - Springer

CY - Cham

ER -

Edrada-Ebel R, Ævarsson A, Polymenakou P, Hentschel U, Carettoni D, Day J et al. SeaBioTech: from seabed to test-bed: harvesting the potential of marine biodiversity for industrial biotechnology. In Rampelotto PH, Trincone A, editors, Grand Challenges in Marine Biotechnology. Cham: Springer. 2018. p. 451-504. (Grand Challenges in Biology and Biotechnology). https://doi.org/10.1007/978-3-319-69075-9_12